{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:14:51Z","timestamp":1760188491405},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[1993,3,1]],"date-time":"1993-03-01T00:00:00Z","timestamp":730944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporosis Int"],"published-print":{"date-parts":[[1993,3]]},"DOI":"10.1007\/bf01623220","type":"journal-article","created":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T01:06:38Z","timestamp":1114909598000},"page":"3-7","source":"Crossref","is-referenced-by-count":15,"title":["Calcitonins: Newer routes of delivery"],"prefix":"10.1007","volume":"3","author":[{"given":"J. Y. L.","family":"Reginster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1210\/endo-70-5-638","volume":"70","author":"DH Copp","year":"1962","unstructured":"Copp DH, Cameron EC, Cheney BA, Davidson AGF, Henze KG. Evidence for calcitonin: a new hormone from the parathyroid that lowers blood calcium. Endocrinology 1962;70:638\u201349.","journal-title":"Endocrinology"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0022-5320(72)90017-2","volume":"39","author":"DM Kallio","year":"1972","unstructured":"Kallio DM, Garant PR, Minkin C. Ultrastructural effects of calcitonin on osteoclasts in tissue culture. J Ultrastruct Mol Struct Res 1972;39:205\u201316.","journal-title":"J Ultrastruct Mol Struct Res"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/BF02405095","volume":"35","author":"TJ Chambers","year":"1983","unstructured":"Chambers TJ, Dunn CJ. Pharmacological control of osteoclastic mobility. Calcif Tissue Int 1983;35:566\u201379.","journal-title":"Calcif Tissue Int"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/endo-107-4-1137","volume":"107","author":"RS Feldman","year":"1980","unstructured":"Feldman RS, Krieger NS, Tashjian AH. Effects of parathyroid hormone and calcitonin on osteoclast formation in vitro. Endocrinology 1980;107:1137\u201343.","journal-title":"Endocrinology"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0168-3659(90)90015-L","volume":"13","author":"AE Pontiroli","year":"1990","unstructured":"Pontiroli AE. Intranasal administration of calcitonin and of other peptides: studies with different promoters. J Controlled Release 1990;13:247\u201351.","journal-title":"J Controlled Release"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/rheumatology\/31.1.35","volume":"31","author":"JY Reginster","year":"1992","unstructured":"Reginster JY, Jeugmans-Huynen AM, Wouters M, Sarlet N, MacIntyre HD, Franchimont P. The effect of nasal hCT on bone turnover in Paget's disease of bone: implications for the treatment of other metabolic bone diseases. Br J Rheumatol 1992;31:35\u20139.","journal-title":"Br J Rheumatol"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1210\/jcem-72-2-344","volume":"72","author":"K Overgaard","year":"1991","unstructured":"Overgaard K, Agnusdei D, Hansen MA, Maioli E, Christiansen C, Gennari C. Dose-response bioactivity and bioavailability of salmon calcitonin in premenopausal and postmenopausal women. J Clin Endocrinol Metab 1991;72:344\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF02555225","volume":"41","author":"T Buclin","year":"1987","unstructured":"Buclin T, Randin JP, Jacquet AF, et al. The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 1987;41:252\u20138.","journal-title":"Calcif Tissue Int"},{"key":"CR9","first-page":"1063","volume":"47","author":"JY Reginster","year":"1990","unstructured":"Reginster JY, Azria M, Gaspar S, et al. The effect of salmon calcitonin on blood ionized calcium in the presence of anti-salmon calcitonin antibodies (from pagetic patients) in young rabbits. Curr Ther Res 1990;47:1063\u201372.","journal-title":"Curr Ther Res"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/03009749009092626","volume":"19","author":"JY Reginster","year":"1990","unstructured":"Reginster JY, Gennari C, Mautalen C, et al. Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatol 1990;19:83\u20136.","journal-title":"Scand J Rheumatol"},{"key":"CR11","first-page":"133","volume":"2","author":"JY Reginster","year":"1987","unstructured":"Reginster JY, Denis D, Albert A, Franchimont P. Assessment of the biological effectiveness of nasal synthetic salmon calcitonin by comparison with intramuscular or placebo injection in normal subjects. Bone Miner 1987;2:133\u201340.","journal-title":"Bone Miner"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/jbmr.5650030302","volume":"3","author":"JY Reginster","year":"1988","unstructured":"Reginster JY, Jeugmans-Huynen AM, Albert A, Denis D, Franchimont P. One year's treatment of Paget's disease of bone by synthetic salmon calcitonin as a nasal spray. J Bone Miner Res 1988;3:249\u201352.","journal-title":"J Bone Miner Res"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(87)92619-5","volume":"2","author":"JY Reginster","year":"1987","unstructured":"Reginster JY, Denis D, Albert A, et al. One-year controlled randomization trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 1987;2:1481\u20133.","journal-title":"Lancet"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2265.1989.tb00443.x","volume":"30","author":"K Overgaard","year":"1989","unstructured":"Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen J. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 1989;30:435\u201342.","journal-title":"Clin Endocrinol"},{"key":"CR15","first-page":"56","volume":"217","author":"CM Nagant de Deuxchaisnes","year":"1987","unstructured":"Nagant de Deuxchaisnes CM, Devogelaer JP, Huaux JP, et al. New modes of administration of salmon calcitonin in Paget's disease. Clin Orthop 1987; 217:56\u201371.","journal-title":"Clin Orthop"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0002-9343(91)90242-P","volume":"1","author":"JY Reginster","year":"1991","unstructured":"Reginster JY. Effect of calcitonin on bone mass and fracture rates. Am J Med 1991;S1:19\u201322.","journal-title":"Am J Med"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bmj.299.6697.477","volume":"299","author":"K Overgaard","year":"1989","unstructured":"Overgaard K, Riis BJ, Christiansen C, Hansen MA. Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 1989;299:477\u20139.","journal-title":"BMJ"},{"key":"CR18","first-page":"1861","volume-title":"Osteoporosis 1990","author":"PJ Meunier","year":"1990","unstructured":"Meunier PJ, Delmas PD, Chaumet-Riffaud PD, et al. Intranasal salmon calcitonin for prevention of postmenopausal bone loss: a placebo-controlled study in 109 women. In: C. Christiansen, K. Overgaard, editors. Osteoporosis 1990. Copenhagen: Osteopress, 1990: 1861\u20137."},{"key":"CR19","first-page":"455","volume-title":"Third international symposium on osteoporosis: abstract book","author":"F Tremolieres","year":"1990","unstructured":"Tremolieres F, Pouilles JM, Horlait S, Guignard M, Ribot C. The role of intranasal salmon calcitonin in the prevention of vertebral and femoral neck bone loss after early menopause. In: C. Christiansen, editor. Third international symposium on osteoporosis: abstract book. Copenhagen: Osteopress, 1990:455."},{"key":"CR20","first-page":"59","volume-title":"Advances in osteoporosis: diagnosis and treatment today","author":"GF Mazzuoli","year":"1989","unstructured":"Mazzuoli GF. Effetti della calcitonia di salmone sommistrate per via nasale in pazienti ovariectomizzate. In: C. Christiansen, editor. Advances in osteoporosis: diagnosis and treatment today. Paris: Masson, 1989:59\u201363."},{"key":"CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(90)90089-V","volume":"89","author":"K Overgaard","year":"1990","unstructured":"Overgaard K, Hansen MA, Hers Nielsen VA, Riis BJ, Christiansen C. Discontinuous calcitonin treatment of established osteoporosis: effect of withdrawal of treatment. Am J Med 1990;89:1\u20136.","journal-title":"Am J Med"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","volume":"305","author":"K Overgaard","year":"1992","unstructured":"Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 1992;305:556\u201361.","journal-title":"BMJ"},{"key":"CR23","first-page":"269","volume-title":"Osteoporosis: physiological basis, assessment and treatment","author":"C Gennari","year":"1990","unstructured":"Gennari C, Agnusdei D, Gonnelli S. Calcitonin and bone pain. In: De Luca H, Mazess R, editors. Osteoporosis: physiological basis, assessment and treatment. Amsterdam: Elsevier, 1990:269\u201374."},{"key":"CR24","first-page":"205","volume":"11","author":"KK Pun","year":"1989","unstructured":"Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 1989;11:205\u20139.","journal-title":"Clin Ther"},{"key":"CR25","first-page":"155","volume":"3","author":"JY Reginster","year":"1985","unstructured":"Reginster JY, Franchimont P. Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin Exp Rheumatol 1985;3:155\u20137.","journal-title":"Clin Exp Rheumatol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01623220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF01623220\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF01623220","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T14:30:47Z","timestamp":1557239447000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF01623220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,3]]},"references-count":25,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[1993,3]]}},"alternative-id":["BF01623220"],"URL":"https:\/\/doi.org\/10.1007\/bf01623220","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,3]]}}}